Bank of New Hampshire Sells 1,645 Shares of Bristol-Myers Squibb (NYSE:BMY)

Bank of New Hampshire lessened its stake in Bristol-Myers Squibb (NYSE:BMY) by 12.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,097 shares of the biopharmaceutical company’s stock after selling 1,645 shares during the quarter. Bank of New Hampshire’s holdings in Bristol-Myers Squibb were worth $602,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of BMY. First National Bank of Mount Dora Trust Investment Services bought a new position in Bristol-Myers Squibb during the first quarter worth about $279,000. Walker Asset Management LLC lifted its stake in shares of Bristol-Myers Squibb by 7.5% during the 1st quarter. Walker Asset Management LLC now owns 6,457 shares of the biopharmaceutical company’s stock valued at $350,000 after buying an additional 450 shares in the last quarter. Banque Cantonale Vaudoise boosted its holdings in Bristol-Myers Squibb by 35.1% in the 1st quarter. Banque Cantonale Vaudoise now owns 144,909 shares of the biopharmaceutical company’s stock worth $7,858,000 after buying an additional 37,663 shares during the period. Legacy Private Trust Co. grew its stake in Bristol-Myers Squibb by 3.5% in the 1st quarter. Legacy Private Trust Co. now owns 11,679 shares of the biopharmaceutical company’s stock valued at $633,000 after buying an additional 400 shares in the last quarter. Finally, Bruce G. Allen Investments LLC raised its holdings in Bristol-Myers Squibb by 26.6% during the 1st quarter. Bruce G. Allen Investments LLC now owns 3,485 shares of the biopharmaceutical company’s stock valued at $189,000 after acquiring an additional 732 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Bristol-Myers Squibb Trading Up 2.2 %

NYSE BMY opened at $41.93 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. The stock has a 50-day moving average of $43.60 and a 200-day moving average of $48.45. The firm has a market cap of $85.00 billion, a PE ratio of -13.53, a price-to-earnings-growth ratio of 13.82 and a beta of 0.43. Bristol-Myers Squibb has a 1-year low of $39.63 and a 1-year high of $65.85.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($4.53) by $0.13. The firm had revenue of $11.87 billion for the quarter, compared to analysts’ expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business’s revenue was up 4.7% on a year-over-year basis. During the same quarter last year, the business earned $2.05 earnings per share. As a group, sell-side analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current year.

Bristol-Myers Squibb Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 1st. Shareholders of record on Friday, July 5th will be given a dividend of $0.60 per share. This represents a $2.40 dividend on an annualized basis and a yield of 5.72%. The ex-dividend date of this dividend is Friday, July 5th. Bristol-Myers Squibb’s payout ratio is -77.42%.

Analyst Ratings Changes

BMY has been the subject of several recent research reports. Societe Generale cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. Wells Fargo & Company lifted their target price on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. BMO Capital Markets lowered their price target on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a report on Friday, April 26th. StockNews.com cut shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research note on Monday, June 17th. Finally, Barclays cut their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $60.00.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.